We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

184 hedge funds and large institutions have $2.04B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 72 increasing their positions, 59 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

509% more call options, than puts

Call options by funds: $178M | Put options by funds: $29.3M

27% more funds holding in top 10

Funds holding in top 10: 11 → 14 (+3)

22% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 59

2% more capital invested

Capital invested by funds: $2.01B → $2.04B (+$35M)

7% less funds holding

Funds holding: 197 → 184 (-13)

26% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 43

Holders
184
Holders Change
-13
Holders Change %
-6.6%
% of All Funds
4.04%
Holding in Top 10
14
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+27.27%
% of All Funds
0.31%
New
32
Increased
72
Reduced
59
Closed
43
Calls
$178M
Puts
$29.3M
Net Calls
+$149M
Net Calls Change
+$47.3M

Top Buyers

Rank Fund Capital Flow
1
CII
Capital International Inc
California
+$45.8M
2
EAM
Eagle Asset Management
Florida
+$41.6M
3
EAM
Eventide Asset Management
Massachusetts
+$34.3M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$21.3M
5
State Street
State Street
Massachusetts
+$19.3M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$15.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$14.1M
3
Franklin Resources
Franklin Resources
California
-$12.7M
4
TAL
TIG Advisors LLC
New York
-$12.6M
5
LM
Luminus Management
Texas
-$12.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
26
ARS Investment Partners
New York
$23.8M +$1.12M +26,585 +5%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$23.4M +$682K +16,148 +3%
Marshall Wace
28
Marshall Wace
United Kingdom
$22.4M +$10.6M +251,836 +88%
BC
29
Broadfin Capital
New York
$22.2M -$6.1M -144,288 -21%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$21.6M +$1.84M +43,520 +9%
Northern Trust
31
Northern Trust
Illinois
$20.4M +$3.85M +91,128 +23%
Capital World Investors
32
Capital World Investors
California
$19.6M – – –
TAL
33
TIG Advisors LLC
New York
$19.2M -$12.6M -297,684 -39%
Norges Bank
34
Norges Bank
Norway
$18.8M – – –
FCMI
35
Foresite Capital Management IV
California
$17.8M -$165K -3,896 -0.9%
CS
36
Candriam SCA
Luxembourg
$17.5M -$1.61M -38,000 -8%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$17.3M +$6.64M +157,079 +61%
GTC
38
Ghost Tree Capital
New York
$14.6M +$10.6M +250,000 +250%
RSCM
39
Rock Springs Capital Management
Maryland
$14.3M – – –
EA
40
Emerald Advisers
Pennsylvania
$13.2M -$887K -21,004 -6%
CWG
41
C WorldWide Group
Denmark
$13M – – –
Goldman Sachs
42
Goldman Sachs
New York
$12.9M +$2.94M +69,567 +29%
EMFAT
43
Emerald Mutual Fund Advisers Trust
Pennsylvania
$12.7M -$60.8K -1,438 -0.5%
CM
44
Caption Management
Oklahoma
$11.2M +$11.4M +268,900 New
BC
45
Blackcrane Capital
Washington
$11.2M +$11.3M +267,728 New
Charles Schwab
46
Charles Schwab
California
$10.9M +$1.71M +40,389 +18%
Invesco
47
Invesco
Georgia
$10.9M +$2.18M +51,706 +25%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$10.9M +$2.96M +70,100 +37%
PAM
49
Panagora Asset Management
Massachusetts
$10.9M +$1.1M +26,045 +11%
Handelsbanken Fonder
50
Handelsbanken Fonder
Sweden
$9.68M +$3.38M +80,000 +53%
1
2
3 4 5

BHVN Hedge Fund Activity: Q3 2019 in Review

184 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2019, worth a combined $2.04B — up 1.7% from $2.01B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of BHVN and 32 opened new positions — a net loss of 11 holders — while 59 trimmed existing stakes and 72 added.

The largest buyer was Capital International Inc, adding an estimated $45.8M. The largest seller was Great Point Partners, exiting entirely with an estimated $15.3M sold.

  • 184 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2019, down from 197 in Q2 2019.
  • Funds reported $2.04B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2019, up 1.7% quarter-over-quarter.
  • 32 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2019 and 43 closed out, a net change of -11 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2019 was Capital International Inc, an estimated $45.8M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2019 was Great Point Partners, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2019.